These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31720303)

  • 1. AAV-Mediated Expression of AP-1-Neutralizing RNA Decoy Oligonucleotides Attenuates Transplant Vasculopathy in Mouse Aortic Allografts.
    Remes A; Franz M; Mohr F; Weber A; Rapti K; Jungmann A; Karck M; Hecker M; Kallenbach K; Müller OJ; Arif R; Wagner AH
    Mol Ther Methods Clin Dev; 2019 Dec; 15():246-256. PubMed ID: 31720303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AAV-mediated AP-1 decoy oligonucleotide expression inhibits aortic elastolysis in a mouse model of Marfan syndrome.
    Remes A; Arif R; Franz M; Jungmann A; Zaradzki M; Puehler T; Heckmann MB; Frey N; Karck M; Kallenbach K; Hecker M; Müller OJ; Wagner AH
    Cardiovasc Res; 2021 Nov; 117(12):2459-2473. PubMed ID: 33471064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AAV-mediated TIMP-1 overexpression in aortic tissue reduces the severity of allograft vasculopathy in mice.
    Remes A; Franz M; Zaradzki M; Borowski C; Frey N; Karck M; Kallenbach K; Müller OJ; Wagner AH; Arif R
    J Heart Lung Transplant; 2020 Apr; 39(4):389-398. PubMed ID: 32035727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of Transplant Vasculopathy by Intraoperative Nucleic Acid-based Therapy in a Mouse Aortic Allograft Model.
    Arif R; Franz M; Remes A; Zaradzki M; Hecker M; Karck M; Müller OJ; Kallenbach K; Wagner AH
    Thorac Cardiovasc Surg; 2019 Sep; 67(6):503-512. PubMed ID: 30352477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AP-1 and STAT-1 decoy oligodeoxynucleotides attenuate transplant vasculopathy in rat cardiac allografts.
    Stadlbauer TH; Wagner AH; Hölschermann H; Fiedel S; Fingerhuth H; Tillmanns H; Bohle RM; Hecker M
    Cardiovasc Res; 2008 Sep; 79(4):698-705. PubMed ID: 18511434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STAT-1 and AP-1 decoy oligonucleotide therapy delays acute rejection and prolongs cardiac allograft survival.
    Hölschermann H; Stadlbauer TH; Wagner AH; Fingerhuth H; Muth H; Rong S; Güler F; Tillmanns H; Hecker M
    Cardiovasc Res; 2006 Aug; 71(3):527-36. PubMed ID: 16822491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common protective and diverse smooth muscle cell effects of AAV-mediated angiopoietin-1 and -2 expression in rat cardiac allograft vasculopathy.
    Nykänen AI; Pajusola K; Krebs R; Keränen MA; Raisky O; Koskinen PK; Alitalo K; Lemström KB
    Circ Res; 2006 Jun; 98(11):1373-80. PubMed ID: 16690881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-octanoyl Dopamine Attenuates the Development of Transplant Vasculopathy in Rat Aortic Allografts Via Smooth Muscle Cell Protective Mechanisms.
    Wedel J; Hottenrott MC; Bulthuis M; Huitema S; Yard BA; Hillebrands JL
    Transplantation; 2016 Jan; 100(1):80-90. PubMed ID: 26674731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolyl-hydroxylase inhibitor activating hypoxia-inducible transcription factors reduce levels of transplant arteriosclerosis in a murine aortic allograft model.
    Heim C; Bernhardt W; Jalilova S; Wang Z; Motsch B; Ramsperger-Gleixner M; Burzlaff N; Weyand M; Eckardt KU; Ensminger SM
    Interact Cardiovasc Thorac Surg; 2016 May; 22(5):561-70. PubMed ID: 26819270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of transplant vasculopathy in aortic allografts correlates with neointimal smooth muscle cell proliferative capacity and fibrocyte frequency.
    Onuta G; van Ark J; Rienstra H; Boer MW; Klatter FA; Bruggeman CA; Zeebregts CJ; Rozing J; Hillebrands JL
    Atherosclerosis; 2010 Apr; 209(2):393-402. PubMed ID: 19913790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutrophils are responsible for impaired medial smooth muscle cell recovery and exaggerated allograft vasculopathy in aortic allografts exposed to prolonged cold ischemia.
    So M; Lee TD; Hancock Friesen CL
    J Heart Lung Transplant; 2013 Mar; 32(3):360-7. PubMed ID: 23415317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AP-1 Oligodeoxynucleotides Reduce Aortic Elastolysis in a Murine Model of Marfan Syndrome.
    Arif R; Zaradzki M; Remes A; Seppelt P; Kunze R; Schröder H; Schwill S; Ensminger SM; Robinson PN; Karck M; Müller OJ; Hecker M; Wagner AH; Kallenbach K
    Mol Ther Nucleic Acids; 2017 Dec; 9():69-79. PubMed ID: 29246325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of differentially expressed genes in rat aortic allograft vasculopathy.
    Chen J; Myllärniemi M; Akyürek LM; Häyry P; Marsden PA; Paul LC
    Am J Pathol; 1996 Aug; 149(2):597-611. PubMed ID: 8701998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alginate hydrogel polymers enable efficient delivery of a vascular-targeted AAV vector into aortic tissue.
    Remes A; Basha DI; Puehler T; Borowski C; Hille S; Kummer L; Wagner AH; Hecker M; Soethoff J; Lutter G; Frank D; Arif R; Frey N; Zaradzki M; Müller OJ
    Mol Ther Methods Clin Dev; 2021 Jun; 21():83-93. PubMed ID: 33768132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus-mediated in vivo gene transfer in a rabbit model of allograft vasculopathy.
    Mehra MR; Stapleton DD; Cook JL; Zhang T; Ventura HO; Huang C; Maldonado B; Smart FW; Re RN; Murgo JP; Barbee RW
    J Heart Lung Transplant; 1996 Jan; 15(1 Pt 1):51-7. PubMed ID: 8820083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Host bone-marrow cells are a source of donor intimal smooth- muscle-like cells in murine aortic transplant arteriopathy.
    Shimizu K; Sugiyama S; Aikawa M; Fukumoto Y; Rabkin E; Libby P; Mitchell RN
    Nat Med; 2001 Jun; 7(6):738-41. PubMed ID: 11385513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of different serotonin receptor subtype antagonists on the development of cardiac allograft vasculopathy in murine aortic allografts.
    Gocht A; Distler JHW; Spriewald B; Ramsperger-Gleixner M; Weyand M; Ensminger SM; Heim C
    Transpl Immunol; 2018 Aug; 49():43-53. PubMed ID: 29649585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates.
    Kawauchi M; Suzuki J; Morishita R; Wada Y; Izawa A; Tomita N; Amano J; Kaneda Y; Ogihara T; Takamoto S; Isobe M
    Circ Res; 2000 Nov; 87(11):1063-8. PubMed ID: 11090553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of combined rapamycin/cyclosporine on the changes in pro-fibrotic gene expression that occur during the development of allograft vasculopathy in rats, compared with cyclosporine or rapamycin in isolation.
    Murphy GJ; Bicknell GR; Nicholson ML
    Transpl Int; 2003 May; 16(5):347-53. PubMed ID: 12759727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapamycin inhibits transplant vasculopathy in long-surviving rat heart allografts.
    Schmid C; Heemann U; Azuma H; Tilney NL
    Transplantation; 1995 Oct; 60(7):729-33. PubMed ID: 7570985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.